Abstract:BMS-690514 ((3R,4R)-4-amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f] [1,2,4] triazin-5-yl)-methyl)-3-piperidinol) is an oral oncologic agent being developed for the treatment of patients with advanced nonsmall cell lung cancer and breast cancer. The compound is metabolized via multiple metabolic pathways, including P450-mediated oxidation at one of the carbons of its pyrrolotriazine group. Oxidation at this site results in the formation of two metabolites, M1 and M37. Mass spectrometric and NMR analysis revealed that M1 underwent an unusual structural change, where the pyrrolotriazine moiety rearranged to yield a hydroxypyridotriazine group. In contrast, the structure of the pyrrolotriazine moiety remained intact in M37. In vitro experiments with liver microsomes and deuterated or tritiated BMS-690514 containing the isotopic label on the carbon that underwent oxidation indicated that during the formation of M1, the isotope label was retained at the site of hydroxylation, while the label was lost during the formation of M37. On the basis of these results, a mechanism for the formation of M1 was proposed as follows: BMS-690514 was first oxidized by P450 enzymes either via epoxidation or an iron-oxo addition pathway to form a zwitterionic intermediate. This was followed by opening of the pyrrolotriazine ring to form an aldehyde intermediate, which could be partially trapped with methoxyamine. The aldehyde intermediate then reacted with the secondary amine of the methoxyaniline group in the molecule to form the pyridotriazine moiety of M1. This mechanism is consistent with the observed retention of the isotope label in M1. Metabolite M37 may be formed either via a common zwitterionic intermediate, shared with M1, or through a direct insertion pathway. In in vitro human liver microsome incubations, the abundance of M1 was higher than M37, suggesting that breaking of the carbon nitrogen bond to generate the aldehyde intermediate, a process similar to N-dealkylation, was a preferred pathway.

Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO).

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Effect of Structural Variation on Aldehyde Oxidase-Catalyzed Oxidation of Zoniporide

Screening, Synthesis, Crystal Structure, and Molecular Basis of 6-Amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles As Novel AKR1C3 Inhibitors.

Aldehyde Oxidase Mediated Metabolism in Drug-like Molecules: A Combined Computational and Experimental Study.

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential anti-prostate cancer agents: design, synthesis, molecular modeling and biological evaluation.

Inhibition of Androgen Receptor Nuclear Localization and Castration Resistant Prostate Tumor Growth by Pyrroloimidazole-Based Small Molecules.

Subtle Structural Changes Across the Boundary Between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives.

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Design and Synthesis of Novel Steroidal Imidazoles As Dual Inhibitors of AR/CYP17 for the Treatment of Prostate Cancer

Design, Synthesis, and Biological Evaluation of Novel Androst-17Β-amide Structurally Related Compounds As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Mechanistic Studies on A P450-Mediated Rearrangement of Bms-690514: Conversion of A Pyrrolotriazine to A Hydroxypyridotriazine

Oxazaphosphorine Bioactivation and Detoxification the Role of Xenobiotic Receptors.

Synthesis, Biological Evaluation and Molecular Docking of 4-Amino-2h-benzo[h]chromen-2-one (ABO) Analogs Containing the Piperazine Moiety.

Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu5-Negative Allosteric Modulator VU0424238 (Auglurant)

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists

Identification of Oral Bioavailable Coumarin Derivatives as Potential AR Antagonists Targeting Prostate Cancer

Design, synthesis and anticancer evaluation of polymethoxy aurones as potential cell cycle inhibitors

Amide-based xanthine oxidase inhibitors bearing an N-(1-alkyl-3-cyano-1H-indol-5-yl) moiety: Design, synthesis and structure-activity relationship investigation